Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
Browse By Topic
Economics & Value
Economics & Value
Articles about real-world healthcare utilization and costs on Value-Based Cancer Care.
Filter by Topic
Accountable Care Organization
Community Oncology
Comparative Effectiveness
Comparative Effectiveness Research
Economics of Cancer Care
Health Economics
Oncology Benefit Edition
Payer-Provider
Pricing
Reimbursement
Value-Based Care
Cost, Access, and Delivery Challenge New Oncology Drug Options
By
Wayne Kuznar
Economics & Value
,
Value in Oncology
December 2016, Vol 7, No 11
Washington, DC—Although significant advancements in oncology research, development, and treatment have improved cancer care, they have been accompanied by rising drug costs, and differences in drug availability and delivery worldwide. These trends will continue into 2020, according to Douglas Long, Vice President, Industry Relations, IMS Health.
Read Article
Value-Based Oncology Management and Outcomes-Based Contracting
By
Wayne Kuznar
Economics & Value
,
Value in Oncology
December 2016, Vol 7, No 11
Washington, DC—An innovative, value-based approach to managing the cost of oncology care moves away from drug-spending volume toward the appropriate use and quality of drug therapy, said Alan Lotvin, MD, Executive Vice President, Specialty Pharmacy, CVS Health, Woonsocket, RI, at the Sixth Annual Conference of the Association for Value-Based Cancer Care.
Read Article
ASCO CEO Addresses Quest for Value in Cancer Care
By
Wayne Kuznar
Economics & Value
,
Value in Oncology
December 2016, Vol 7, No 11
Washington, DC—Treatments and technologies for cancer care are becoming increasingly expensive, fueling a need to define and improve value. As a result, the American Society of Clinical Oncology (ASCO) is refining its value framework that supports informed shared decision-making between doctors and patients and considers the clinical benefit, cost, and toxicity of cancer treatments. The goal is to have a tool that can customize information for each patient.
Read Article
Quality Measures Are Key to Supporting Drug Value
By
Wayne Kuznar
Economics & Value
,
Value in Oncology
December 2016, Vol 7, No 11
Washington, DC—An opportunity for value enhancement from the drug manufacturer’s perspective includes the improved use of data to meet the needs of stakeholders, especially the patient. Data that are generated should support the value of the manufacturer’s therapies in light of newly established value-based models, which often rely on quality metrics, for example, that are not obvious from clinical trials. Finally, wraparound services can add to a drug’s value and help to distinguish it from a competitor’s drug.
Read Article
Cancer Treatment Costs and Trends Beckon Risk-Sharing Future
By
Wayne Kuznar
Economics & Value
,
Value in Oncology
December 2016, Vol 7, No 11
Washington, DC—Oncology care is facing rising costs that will demand a transformation from a fee-for-service reimbursement model to a value-based, shared-risk incentive plan for Medicare and commercial insurance plans. Bruce Pyenson, FSA, MAAA, Principal and Consulting Actuary, Milliman, New York, NY, provided an overview of the cost trends of cancer treatment costs at the Sixth Annual Conference of the Association for Value-Based Cancer Care.
Read Article
Value-Based Care Must Be Linked to Improved Clinical Outcomes
By
James T. Kenney, RPh, MBA
Economics & Value
,
Payer’s Perspective
,
Value-Based Care
,
Value Peer-spectives
February 2016, Vol 7, No 1
Society meetings, such as the recent American Society of Hematology (ASH) annual meeting, generate a lot of clinical-related excitement regarding new treatment options, protocols, and pathways for hematologic cancers.
Read Article
Measuring Value in Healthcare to Improve Quality
By
Chase Doyle
Economics & Value
,
Value in Oncology
February 2016, Vol 7, No 1
Medicare is poised to incorporate new quality metrics as a guide for payments. At ASH 2015, Helen Burstin, MD, MPH, Chief Scientific Officer, National Quality Forum, Washington, DC, discussed the need for measures and reporting systems that reflect patient care and care coordination.
Read Article
Value-Based Oncology Center of Excellence Model
By
Kelly Blair, MPA
Economics & Value
,
Value in Oncology
,
Value-Based Care
November 2015, Vol 6, No 10
“Centers of Excellence” (COEs) is not a new concept in healthcare. The underlying hypothesis is that providers who specialize in a particular procedure or service will produce superior, predictable outcomes. Payers have developed COE networks to manage cost and quality for complex medical conditions for more than 2 decades, steering volume to high-performing providers in exchange for discounted contractual rates. Under significant pressure to reduce the burden of cancer spending, payers are beginning to make bold network decisions, including narrowing networks, but they need precision tools to ensure that quality of care is uncompromised, and even improved, while reining in unsustainable cost trends.
Read Article
Current Practice Least Cost-Effective Option in Prostate Cancer Management
By
Meg Barbor, MPH
Economics & Value
,
Economics of Cancer Care
October 2015, Vol 6, No 9
Copenhagen, Denmark—Current follow-up strategy for patients with prostate cancer was found to be the least cost-effective approach in an analysis conducted in Europe.
Read Article
Whole-Brain Radiotherapy for Brain Metastases Is Cost-Effective
By
Rosemary Frei, MSc
Economics & Value
,
Economics of Cancer Care
October 2015, Vol 6, No 9
The treatment of patients with brain metastases involves issues of controlling recurrence, side effects, and costs.
Read Article
Page 4 of 18
1
2
3
4
5
6
7
8
9
10
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Navigating the Complex Landscape of Oral Cancer Medication
2.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
3.
New NCCN Guidelines for CLL/SLL Include Second-Generation BTK Inhibitors
Wayne Kuznar
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma